On the last full day of the BIO Convention, Tom Watkins, President and CEO of Human Genome Sciences and Chairman of the Board for BIO, reviewed the major policy advocacy activities of BIO over the past year at the Keynote luncheon session.
BIO has advocated for expedited approval of biosimilars in the passage of the Biosimilars User Fees act (BsUFA), and has been working to ensure policy changes that enhance transparency and help minimize review times FDA approvals are included in the fifth renewal of the Prescription Drug User Fee Act (PDUFA) which is anticipated to pass later this year.
{iframe}http://biotech.about.com/b/2012/06/21/day-3-of-bio-2012-bio-advocacy-ted-kennedys-legacy-and-opinion-poll-on-the-outlook-of-biotech.htm{/iframe}